News and updates with the latest clinical trials, medical reports and interesting developments within the DMD community.
This will significantly expand trial capacity for Duchenne Muscular Dystrophy in the UK, particularly in the north west of England.
The charity's co-founder Alex Johnson -- recently awarded the Pride of Manchester -- said it was a huge boost to research in the region.
We are pleased to announce that Catabasis Pharmaceutical's PolarisDMD Phase 3 trial for edasalonexent is now recruiting in the UK at Bristol Royal Hospital for Children. Evelina London Children's Hospital, Great Ormond Street Hospital and Royal Manchester Children’s Hospital will begin recruitment soon.
We are pleased to announce that the VISION-DMD Phase 2b clinical trial has begun recruitment at Newcastle upon Tyne NHS Hospital Foundation Trust and Royal Hospital for Children, Glasgow.
This article was originally published on Muscular Dystrophy News.
Bristol Royal Hospital for Children joins the DMD Hub as a Hub site.
Duchenne UK is pleased to share a report from Great Ormond Street about the positive impact of the clinical staff posts we fund at the hospital.
Duchenne UK announces £46,930 in funding at Birmingham Heartlands Hospital. This funding will provide dedicated consultant time to DMD trials and provide physiotherapy equipment.
Last Thursday, our co-founder Alex Johnson attended the opening of the Clinical Research Facility at Leeds Children's Hospital which has recently joined the DMD Hub.
Duchenne UK is pleased to announce the launch of the DMD Hub website, the go-to website for clinical trial information for Duchenne Muscular Dystrophy (DMD) in the UK.
The DMD Hub was created by Duchenne UK and leading neuromuscular clinicians based at the John Walton Muscular Dystrophy Research Centre in Newcastle and Great Ormond Street Hospital in London. The DMD-Hub is addressing the lack of capacity in the UK for clinical trials in Duchenne Muscular Dystrophy. Our ambition is to ensure that every child diagnosed with DMD in the UK is given the opportunity to take part in research.